Lantheus announces FDA approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection. Learn more.

Because we’re making headlines

Please visit our investor site for a complete list of recent and archived press releases, follow us on LinkedIn for social media updates and browse below for additional media resources.

Latest press releases

See all press releases

Press release

February 23, 2023

Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results

Read more

Press release

February 16, 2023

Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels

Read more

Press release

February 9, 2023

Lantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8:00 a.m. Eastern Time

Read more

Additional resources

Media library

Images, videos and other assets bring news about Lantheus to life.

Events

Events allow us to connect with our people, patients and partners.

Investors

All investor resources can be found on our dedicated investor website.

Contact

Media

Melissa Downs
Executive Director
External Communications

646-975-2533

media@lantheus.com

Investors

Mark Kinarney
Vice President
Investor Relations

978-671-8842

ir@lantheus.com